CASI Pharmaceuticals (CASIF) Payables (2021 - 2025)

CASI Pharmaceuticals has reported Payables for 5 years, with the latest figure at $25.2 million in Q4 2025.

• For the quarter ending Q4 2025, Payables rose 824.42% year-over-year to $25.2 million; the trailing twelve-month figure through Dec 2025 stood at $25.2 million (up 824.42% YoY), and the FY2025 full-year result was $25.2 million, up 824.42% from the prior year.
• Payables for Q4 2025 stood at $25.2 million, up from $2.7 million in the prior quarter.
• The five-year high for Payables was $25.2 million in Q4 2025, with the low at $2.2 million in Q4 2021.
• Historically, Payables has averaged $7.6 million across 5 years, with a median of $3.3 million in 2022.
• Annual changes were most pronounced in 2024 — Payables tumbled 38.64% — and 2025, when it surged 824.42%.
• CASI Pharmaceuticals' Payables stood at $2.2 million in 2021, then soared by 47.95% to $3.3 million in 2022, then jumped by 34.93% to $4.4 million in 2023, then sank by 38.64% to $2.7 million in 2024, then surged by 824.42% to $25.2 million in 2025.
• The last three Payables figures came in at $25.2 million (Q4 2025), $2.7 million (Q4 2024), and $4.4 million (Q4 2023), per Business Quant data.